BindingDB logo
myBDB logout

null

SMILES: OC(=O)C1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3C2CCCCCCCCC2)c1=O

InChI Key: InChIKey=LGVPDQRPYCFJGT-LNWKWYTESA-N

Find this compound or compounds like it in BindingDB or PDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 220374   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))
BDBM220374
PNG
(US9290488, H3a)
Show SMILES OC(=O)C1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3C2CCCCCCCCC2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H42N4O3/c35-29-28(32-19-21(20-32)30(36)37)31-26-15-8-9-16-27(26)34(29)25-17-23-13-10-14-24(18-25)33(23)22-11-6-4-2-1-3-5-7-12-22/h8-9,15-16,21-25H,1-7,10-14,17-20H2,(H,36,37)/t23-,24+,25+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
9.93 -10.9n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...


US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))
BDBM220374
PNG
(US9290488, H3a)
Show SMILES OC(=O)C1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3C2CCCCCCCCC2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H42N4O3/c35-29-28(32-19-21(20-32)30(36)37)31-26-15-8-9-16-27(26)34(29)25-17-23-13-10-14-24(18-25)33(23)22-11-6-4-2-1-3-5-7-12-22/h8-9,15-16,21-25H,1-7,10-14,17-20H2,(H,36,37)/t23-,24+,25+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 40.1n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...


US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair